---
title: "Diabetic Neuropathy"
description: "Clinical decision support for diabetic peripheral neuropathy diagnosis and management"
version: "1.0"
setting: "ED, HOSP, OPD"
status: approved
tags:
  - neuropathy
  - diabetes
  - pain
  - outpatient
---

# Diabetic Neuropathy

**DIAGNOSIS:** Diabetic Peripheral Neuropathy
**ICD-10:** G63.2 (Diabetic polyneuropathy); E11.42 (Type 2 DM with diabetic polyneuropathy); E10.42 (Type 1 DM with diabetic polyneuropathy)
**SCOPE:** Distal symmetric polyneuropathy (most common), painful diabetic neuropathy treatment, foot care, and screening for other diabetic neuropathy types. Excludes diabetic amyotrophy (separate protocol) and autonomic neuropathy (mentioned but not primary focus).

**STATUS:** Approved

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

## SECTION A: ACTION ITEMS

---

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| HbA1c | Assess glycemic control; primary modifiable risk factor | <7% (individualized goals for elderly) | - | ROUTINE | ROUTINE | - |
| Fasting glucose | Current glycemic status | 70-130 mg/dL | STAT | ROUTINE | ROUTINE | - |
| BMP (including creatinine, eGFR) | Renal function for medication dosing; CKD common in diabetes | eGFR >60 preferred; adjust meds if lower | STAT | ROUTINE | ROUTINE | - |
| Lipid panel | Cardiovascular risk; dyslipidemia common comorbidity | LDL <100 mg/dL (or <70 if ASCVD) | - | ROUTINE | ROUTINE | - |
| Vitamin B12 | Metformin causes B12 deficiency; mimics diabetic neuropathy | >300 pg/mL (>400 optimal) | - | ROUTINE | ROUTINE | - |
| TSH | Hypothyroidism causes neuropathy; common comorbidity | 0.4-4.0 mIU/L | - | ROUTINE | ROUTINE | - |
| CBC | Anemia evaluation; baseline | Normal | STAT | ROUTINE | ROUTINE | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Methylmalonic acid (MMA) | More sensitive for B12 deficiency if B12 borderline | Normal | - | ROUTINE | ROUTINE | - |
| Folate | Deficiency contributes to neuropathy | >3 ng/mL | - | ROUTINE | ROUTINE | - |
| Vitamin D | Deficiency associated with neuropathic pain | >30 ng/mL | - | ROUTINE | ROUTINE | - |
| SPEP/UPEP with immunofixation | Rule out paraproteinemia if atypical features | No monoclonal protein | - | ROUTINE | ROUTINE | - |
| ANA | Autoimmune/vasculitic neuropathy if atypical | Negative | - | EXT | ROUTINE | - |
| ESR, CRP | Inflammatory markers if vasculitis suspected | Normal | - | ROUTINE | ROUTINE | - |
| Hepatitis B, C serologies | Hepatitis C associated with neuropathy; prevalence in diabetics | Negative | - | ROUTINE | ROUTINE | - |
| HIV | HIV neuropathy if risk factors | Negative | - | EXT | EXT | - |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Cryoglobulins | Cryoglobulinemic neuropathy (esp. with Hep C) | Negative | - | - | EXT | - |
| Anti-MAG antibodies | IgM paraprotein-associated neuropathy | Negative | - | - | EXT | - |
| Genetic neuropathy panel (CMT genes) | Family history; atypical presentation | Negative | - | - | EXT | - |
| Nerve biopsy | Vasculitic neuropathy suspected; atypical non-length-dependent | Diagnostic findings | - | - | EXT | - |
| Skin biopsy for IENFD | Quantify small fiber neuropathy | Reduced intraepidermal nerve fiber density | - | - | ROUTINE | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Monofilament testing (10g) | At every diabetic visit; annually minimum | Intact sensation 8-10 sites | None | - | ROUTINE | ROUTINE | - |
| Tuning fork (128 Hz) | Vibration sense at great toe | Intact vibration sense | None | - | ROUTINE | ROUTINE | - |
| Ankle reflexes | Deep tendon reflex assessment | Present (may be diminished/absent in neuropathy) | None | - | ROUTINE | ROUTINE | - |
| Foot examination | Inspect for ulcers, calluses, deformities, pulses | No ulcers or pre-ulcerative lesions | None | STAT | ROUTINE | ROUTINE | - |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| EMG/NCS (nerve conduction study) | Atypical presentation; asymmetric; rapid progression | Length-dependent sensory > motor polyneuropathy | Anticoagulation (relative for EMG) | - | ROUTINE | ROUTINE | - |
| Autonomic testing (QSART, HR variability, tilt table) | Symptoms of autonomic neuropathy; syncope; gastroparesis | Abnormal sudomotor, cardiovagal, or adrenergic function | None | - | EXT | ROUTINE | - |
| MRI lumbar spine | Radiculopathy suspected; focal deficits | Rule out compressive lesion | MRI contraindications | URGENT | ROUTINE | ROUTINE | - |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| Skin biopsy (punch biopsy at ankle and thigh) | Confirm small fiber neuropathy; normal NCS | Reduced IENFD (<threshold for age/sex) | Bleeding diathesis; anticoagulation | - | - | ROUTINE | - |
| Corneal confocal microscopy | Research; non-invasive small fiber assessment | Reduced corneal nerve fiber length/density | None | - | - | EXT | - |
| Sudoscan | Screening for sudomotor dysfunction; small fiber | Abnormal electrochemical skin conductance | None | - | - | EXT | - |

---

## 3. TREATMENT

### 3A. Acute/Emergent

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Wound care | Topical | Diabetic foot ulcer | Debridement; offloading; appropriate dressing :: Topical :: :: Wound assessment; debridement if needed; offload pressure; moist wound healing | None | Signs of infection; healing progress | STAT | STAT | ROUTINE | - |
| Antibiotics (diabetic foot infection) | PO/IV | Infected diabetic foot ulcer | Per culture/severity :: PO/IV :: :: Mild: oral (cephalexin, amox/clav); Moderate-severe: IV (piptazo, vanc); per wound culture | Drug allergy | Infection markers; wound healing | STAT | STAT | - | - |
| Pain crisis management | IV/PO | Severe acute neuropathic pain flare | Multimodal :: IV/PO :: :: Consider IV lidocaine if refractory; short-term low-dose opioid for acute crisis | Per specific agent | Pain scores; sedation | URGENT | URGENT | - | - |

### 3B. Symptomatic Treatments (Neuropathic Pain - First-line)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Duloxetine | PO | First-line for painful diabetic neuropathy; FDA-approved | 30 mg daily; 60 mg daily :: PO :: :: Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day (limited evidence for higher doses) | MAOIs; uncontrolled glaucoma; severe renal impairment (CrCl <30) | Hepatic function; BP; suicidal ideation | - | ROUTINE | ROUTINE | - |
| Pregabalin | PO | First-line; FDA-approved for DPN | 50 mg TID; 75 mg BID; 100 mg TID; 150 mg BID; 200 mg TID :: PO :: :: Start 50 mg TID or 75 mg BID; titrate q3-7d based on response; max 300 mg/day (CrCl 30-60: reduce dose) | Angioedema to pregabalin/gabapentin | Dizziness, somnolence, weight gain, peripheral edema | - | ROUTINE | ROUTINE | - |
| Gabapentin | PO | First-line alternative; less expensive; similar efficacy | 300 mg qHS; 300 mg TID; 600 mg TID; 900 mg TID; 1200 mg TID :: PO :: :: Start 300 mg qHS; titrate by 300 mg q3-7d; target 1800-3600 mg/day divided TID; reduce dose if CrCl <60 | Severe renal impairment (dose adjust) | Same as pregabalin; less edema | - | ROUTINE | ROUTINE | - |
| Amitriptyline | PO | TCA option; also helps sleep; less expensive | 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS; 100 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS; max 150 mg | Cardiac conduction abnormality; recent MI; urinary retention; glaucoma; elderly (use with caution) | ECG if >40y or cardiac history; anticholinergic effects | - | ROUTINE | ROUTINE | - |
| Nortriptyline | PO | TCA with less sedation and anticholinergic effects than amitriptyline | 10 mg qHS; 25 mg qHS; 50 mg qHS; 75 mg qHS :: PO :: :: Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; typical 25-75 mg qHS | Same as amitriptyline | Same as amitriptyline; ECG if >100 mg | - | ROUTINE | ROUTINE | - |
| Venlafaxine XR | PO | SNRI alternative to duloxetine | 37.5 mg daily; 75 mg daily; 150 mg daily; 225 mg daily :: PO :: :: Start 37.5 mg daily; titrate by 37.5-75 mg q1wk; target 150-225 mg daily | MAOIs; uncontrolled HTN | BP at higher doses; withdrawal if abrupt discontinuation | - | ROUTINE | ROUTINE | - |

### 3C. Second-line/Refractory (Neuropathic Pain)

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Capsaicin 8% patch (Qutenza) | Topical | Localized neuropathic pain; add-on therapy | Apply for 30 min :: Topical :: :: Applied by healthcare provider; local anesthetic pre-treatment; repeat q3mo | Application to face; broken skin | Local pain during application; burning | - | - | ROUTINE | - |
| Lidocaine 5% patch | Topical | Localized pain; adjunctive therapy | 1-3 patches to painful area :: Topical :: :: Apply to most painful area; up to 3 patches for 12h on/12h off | Allergy to local anesthetics | Skin irritation | - | ROUTINE | ROUTINE | - |
| Tapentadol ER | PO | Refractory pain; opioid with norepinephrine reuptake inhibition | 50 mg BID; 100 mg BID; 150 mg BID; 200 mg BID; 250 mg BID :: PO :: :: Start 50 mg BID; titrate by 50 mg BID q3d; max 500 mg/day; FDA-approved for DPN | Severe respiratory depression; MAOIs; paralytic ileus | Constipation, sedation, respiratory status | - | EXT | ROUTINE | - |
| Tramadol | PO | Moderate pain; opioid-like with serotonergic properties | 50 mg q6h PRN; 100 mg ER BID :: PO :: :: Start 50 mg q6h PRN; max 400 mg/day; reduce if renal/hepatic impairment | Seizure disorder; concurrent MAOIs/SSRIs (serotonin syndrome risk) | Seizures, serotonin syndrome, sedation | - | ROUTINE | ROUTINE | - |
| Desipramine | PO | TCA with minimal anticholinergic effects | 25 mg qHS; 50 mg qHS; 100 mg qHS :: PO :: :: Start 25 mg qHS; titrate by 25 mg q1-2wk; target 50-100 mg | Same as other TCAs | ECG; therapeutic drug monitoring available | - | ROUTINE | ROUTINE | - |
| Oxcarbazepine | PO | Second-line anticonvulsant; less evidence | 300 mg BID; 600 mg BID :: PO :: :: Start 300 mg BID; titrate by 300 mg/wk; typical 600-1200 mg/day | Hyponatremia risk | Sodium level; rash (SJS rare) | - | - | ROUTINE | - |
| Combination therapy | Various | Inadequate response to single agent | Combine agents from different classes :: Various :: :: Use lower doses of each; duloxetine + pregabalin; TCA + gabapentinoid | Per individual agents | Additive side effects | - | ROUTINE | ROUTINE | - |
| Buprenorphine patch | TD | Severe refractory pain; opioid option | 5 mcg/hr; 10 mcg/hr; 20 mcg/hr :: TD :: :: Start 5 mcg/hr weekly patch; titrate slowly | Severe respiratory depression; QT prolongation | Respiratory status, QTc | - | EXT | ROUTINE | - |
| Spinal cord stimulation | Implant | Refractory painful DPN; failed multiple medications | Per implant protocol :: Implant :: :: Trial stimulation before permanent; high-frequency or burst stimulation | Infection; coagulopathy; psychiatric instability | Device function; pain relief | - | - | EXT | - |

### 3D. Disease-Modifying / Preventive Therapies

| Treatment | Route | Indication | Dosing | Pre-Treatment Requirements | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|---------------------------|-------------------|------------|:--:|:----:|:---:|:---:|
| Glycemic control optimization | Various | Primary prevention and slowing progression | HbA1c target <7% :: Various :: :: Individualized; tighter control (6-6.5%) in younger patients; less strict (7.5-8%) in elderly/comorbid | None | Hypoglycemia risk | HbA1c q3mo until at goal, then q6mo | - | ROUTINE | ROUTINE | - |
| Alpha-lipoic acid | PO/IV | Antioxidant; European data for DPN | 600 mg daily; 600 mg IV daily :: PO/IV :: :: 600 mg PO daily; IV form (600 mg daily x 3wk) for acute symptom relief; limited evidence | None | GI upset; may lower glucose | Glucose (may enhance insulin sensitivity) | - | ROUTINE | ROUTINE | - |
| Vitamin B12 supplementation | PO/IM | B12 deficiency or metformin use | 1000 mcg PO daily; 1000 mcg IM monthly :: PO/IM :: :: 1000-2000 mcg PO daily; or 1000 mcg IM monthly if poor absorption | None | None | B12 level q6-12mo | - | ROUTINE | ROUTINE | - |
| Benfotiamine | PO | Thiamine derivative; AGE inhibition | 300 mg BID :: PO :: :: 300 mg BID; limited evidence | None | GI upset | None specific | - | - | ROUTINE | - |
| ACE inhibitor or ARB | PO | Nephroprotection; may slow neuropathy progression | Per agent :: PO :: :: Standard doses; benefit for kidney protection proven; neuropathy benefit theoretical | Angioedema; pregnancy; hyperkalemia; bilateral RAS | K+, creatinine | - | ROUTINE | ROUTINE | - |
| Statin therapy | PO | Cardiovascular protection; anti-inflammatory | Per agent :: PO :: :: High-intensity statin for most diabetics | Active liver disease | LFTs, myalgias | - | ROUTINE | ROUTINE | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Endocrinology for diabetes optimization if HbA1c not at goal or complex regimen needed | - | ROUTINE | ROUTINE | - |
| Podiatry for foot exam, nail care, custom orthotics, and offloading devices | - | ROUTINE | ROUTINE | - |
| Vascular surgery if peripheral arterial disease suspected (ABI <0.9 or absent pulses) | URGENT | URGENT | ROUTINE | - |
| Pain management for refractory neuropathic pain and interventional options (SCS) | - | - | ROUTINE | - |
| Physical therapy for balance training and gait assessment to reduce fall risk | - | ROUTINE | ROUTINE | - |
| Wound care specialist for diabetic foot ulcers not healing with standard care | - | URGENT | ROUTINE | - |
| Ophthalmology for annual diabetic retinopathy screening | - | - | ROUTINE | - |
| Nephrology if eGFR <30 or rapidly declining renal function | - | ROUTINE | ROUTINE | - |

### 4B. Patient Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Inspect feet daily using mirror for soles; look for cuts, blisters, redness, or swelling | - | ROUTINE | ROUTINE |
| Never walk barefoot, even indoors, to prevent foot injuries | - | ROUTINE | ROUTINE |
| Wear properly fitted shoes with adequate support; have shoes fitted by professional | - | ROUTINE | ROUTINE |
| Test bath water temperature with elbow (not feet) to prevent burns from impaired sensation | - | ROUTINE | ROUTINE |
| Report any foot wounds, color changes, or pain immediately as diabetic foot ulcers can progress rapidly | STAT | STAT | ROUTINE |
| Take all prescribed medications as directed; do not skip doses of pain medications abruptly | - | ROUTINE | ROUTINE |
| Monitor blood glucose as directed; excellent glycemic control is the most important factor to slow progression | - | ROUTINE | ROUTINE |
| Avoid alcohol which can worsen neuropathy and interact with pain medications | - | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Optimal glycemic control (HbA1c <7%) is the primary intervention to prevent and slow neuropathy progression | - | ROUTINE | ROUTINE |
| Smoking cessation as smoking worsens peripheral vascular disease and neuropathy | - | ROUTINE | ROUTINE |
| Blood pressure control (<130/80) reduces microvascular complications | - | ROUTINE | ROUTINE |
| LDL cholesterol control with statin therapy reduces cardiovascular risk | - | ROUTINE | ROUTINE |
| Regular physical activity (150 min/week moderate) improves glycemic control and overall health | - | ROUTINE | ROUTINE |
| Healthy diet (Mediterranean or DASH) supports glycemic and cardiovascular goals | - | ROUTINE | ROUTINE |
| Limit alcohol which worsens neuropathy independently and affects glycemic control | - | ROUTINE | ROUTINE |
| Annual comprehensive foot examination by healthcare provider | - | - | ROUTINE |
| Fall prevention with home safety modifications given impaired proprioception | - | ROUTINE | ROUTINE |

---

## SECTION B: REFERENCE

---

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| B12 deficiency neuropathy | Sensory > motor; may have subacute combined degeneration; metformin use | B12, MMA levels |
| Chronic inflammatory demyelinating polyneuropathy (CIDP) | Motor involvement; areflexia; elevated CSF protein; demyelinating NCS | EMG/NCS (demyelinating pattern); CSF protein |
| Uremic neuropathy | Advanced CKD (eGFR <15); improves with dialysis | BUN, creatinine, eGFR |
| Alcoholic neuropathy | Heavy alcohol use history; painful; coexisting thiamine deficiency | History; thiamine level |
| Hypothyroid neuropathy | Other hypothyroid symptoms; CTS common | TSH, free T4 |
| Paraproteinemic neuropathy | IgM most common; anti-MAG antibodies; may have ataxia | SPEP/UPEP; immunofixation; anti-MAG |
| Chemotherapy-induced neuropathy | Temporal relationship with chemotherapy (platinum, taxanes, vincristine) | Medication history |
| Hereditary neuropathy (CMT) | Family history; high arches (pes cavus); hammer toes; slowly progressive | Genetic testing; NCS pattern |
| Vasculitic neuropathy | Asymmetric; mononeuritis multiplex pattern; systemic symptoms | Nerve biopsy; inflammatory markers; angiography |
| Amyloid neuropathy | Autonomic involvement; cardiomyopathy; carpal tunnel; paraprotein may be present | Fat pad or nerve biopsy; genetic testing (TTR); SPEP |

---

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| HbA1c | Every 3-6 months | <7% (individualized) | Intensify diabetes management | - | ROUTINE | ROUTINE | - |
| Comprehensive foot exam | Annually (more often if high risk) | No ulcers, intact sensation, intact skin | Podiatry referral; offloading; wound care | - | ROUTINE | ROUTINE | - |
| Monofilament testing | At least annually | Intact sensation at â‰¥8/10 sites | High-risk foot care; education | - | ROUTINE | ROUTINE | - |
| Pain scores (VAS, NRS) | Each visit | 50%+ reduction with treatment | Adjust therapy; consider combination or referral | - | ROUTINE | ROUTINE | - |
| B12 level | Annually if on metformin | >300 pg/mL | Supplement B12 | - | ROUTINE | ROUTINE | - |
| Kidney function (eGFR) | At least annually | eGFR >60; stable | Adjust medication doses; nephrology referral if declining | - | ROUTINE | ROUTINE | - |
| Blood pressure | Each visit | <130/80 mmHg | Optimize antihypertensives | - | ROUTINE | ROUTINE | - |
| Autonomic symptoms screen | Each visit | No symptoms | Autonomic testing; cardiology referral if cardiac autonomic neuropathy | - | ROUTINE | ROUTINE | - |
| Depression screen (PHQ-9) | Annually or if symptoms | Negative | Treatment; referral | - | ROUTINE | ROUTINE | - |

---

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge home | Symptoms managed; no foot infection; follow-up arranged |
| Admit to floor | Diabetic foot infection requiring IV antibiotics; severe uncontrolled pain; associated acute kidney injury |
| Surgical admission | Foot infection requiring debridement or amputation |
| Outpatient follow-up | Every 3-6 months for medication optimization; annually for comprehensive foot exam |

---

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| Duloxetine for painful DPN (FDA-approved) | Class I, Level A | [Wernicke et al. Neurology 2006](https://pubmed.ncbi.nlm.nih.gov/17060567/) |
| Pregabalin for painful DPN (FDA-approved) | Class I, Level A | [Derry et al. Cochrane 2019](https://pubmed.ncbi.nlm.nih.gov/30673120/) |
| Gabapentin effective for DPN | Class II, Level B | [Wiffen et al. Cochrane 2017](https://pubmed.ncbi.nlm.nih.gov/28597471/) |
| Tricyclic antidepressants effective | Class II, Level B | [Moore et al. Cochrane 2015](https://pubmed.ncbi.nlm.nih.gov/25879104/) |
| Glycemic control prevents neuropathy progression | Class I, Level A | [DCCT/EDIC Research Group. NEJM 1993](https://pubmed.ncbi.nlm.nih.gov/8366922/) |
| Alpha-lipoic acid may improve symptoms | Class II, Level B | [Ziegler et al. Diabetes Care 2011](https://pubmed.ncbi.nlm.nih.gov/21994426/) |
| Comprehensive foot exam reduces amputations | Class II, Level B | [ADA Standards of Care 2024 (Section 12)](https://pubmed.ncbi.nlm.nih.gov/38078577/) |
| Tapentadol effective for DPN (FDA-approved) | Class I, Level A | [Vinik et al. Diabetes Care 2014](https://pubmed.ncbi.nlm.nih.gov/24947790/) |
| Spinal cord stimulation for refractory DPN | Class II, Level B | [Slangen et al. Diabetes Care 2014](https://pubmed.ncbi.nlm.nih.gov/24947789/) |
| Capsaicin 8% patch effective | Class I, Level A | [Simpson et al. Pain 2017](https://pubmed.ncbi.nlm.nih.gov/27479770/) |

---

## CHANGE LOG

**v1.0 (January 27, 2026)**
- Initial template creation
- Comprehensive neuropathic pain management
- Includes FDA-approved agents (duloxetine, pregabalin, tapentadol)
- Foot care and ulcer prevention emphasis
- Structured dosing format for order sentence generation

---

## APPENDIX A: Diabetic Foot Risk Classification

| Risk Category | Features | Foot Exam Frequency | Recommendations |
|---------------|----------|---------------------|-----------------|
| Low risk | Normal sensation; no deformity; palpable pulses | Annually | Education; appropriate footwear |
| Moderate risk | Loss of protective sensation OR peripheral artery disease OR foot deformity | Every 3-6 months | Podiatry referral; custom footwear consideration |
| High risk | Previous ulcer OR previous amputation OR end-stage renal disease | Every 1-3 months | Podiatry; vascular evaluation; offloading devices |
| Active ulcer or infection | Current ulcer/infection | As needed until healed | Wound care team; vascular surgery if ischemic |

## APPENDIX B: Types of Diabetic Neuropathy

| Type | Clinical Features | Typical Onset | Prognosis |
|------|-------------------|---------------|-----------|
| **Distal symmetric polyneuropathy (DSPN)** | Stocking-glove sensory loss; burning pain; numbness; length-dependent | Insidious | Chronic; preventable progression with glycemic control |
| **Diabetic autonomic neuropathy** | Orthostatic hypotension; gastroparesis; erectile dysfunction; sudomotor dysfunction; cardiac denervation | Gradual | Variable; cardiac autonomic neuropathy increases mortality |
| **Diabetic lumbosacral radiculoplexus neuropathy (diabetic amyotrophy)** | Acute/subacute proximal leg weakness and pain; weight loss; often unilateral then spreads | Acute-subacute | Usually monophasic; recovery over months-years |
| **Diabetic thoracic radiculopathy** | Truncal pain/dysesthesia; dermatomal distribution; may mimic visceral disease | Acute-subacute | Self-limited (months) |
| **Cranial neuropathy** | CN III most common (pupil-sparing); CN VI, VII also affected | Acute | Usually resolves in 3-6 months |
| **Mononeuropathy/entrapment** | Carpal tunnel syndrome; ulnar neuropathy; peroneal neuropathy | Variable | Treat underlying entrapment |
| **Treatment-induced neuropathy of diabetes (TIND)** | Acute painful small fiber neuropathy after rapid glucose improvement | After aggressive glycemic control | Usually improves with slower glucose normalization |
